CNS Cancer | Norton Healthcare

Indication: CNS Cancer

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy


Sub-indication: Grade 3 Astrocytoma, Recurrent

Line of Therapy: Second line

Drug Study

Principal Investigator: Renato LaRocca, M.D.
Norton Cancer Institute

Sponsor: Orbus Therapeutic Inc

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.